1600. An Optimal Respiratory Syncytial Virus (RSV) Treatment in Lung Transplant Recipients: Oral Ribavirin, Inhaled Ribavirin, or Conservative Approach
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.1428
Abstract: Abstract Background Respiratory syncytial virus (RSV) is a common community acquired infection in lung transplant recipients (LTRs). The mortality in RSV-infected LTRs has been reported as 10–20% despite antiviral therapy; however, there is no consensus… read more here.
Keywords: rbv; oral rbv; infection; rsv ... See more keywords
Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients
Sign Up to like & getrecommendations! Published in 2019 at "Transplantation"
DOI: 10.1097/tp.0000000000002985
Abstract: Background. Respiratory syncytial virus (RSV) infection in lung transplant recipients (LTRs) causes mortality rates of 10%–20% despite antiviral therapy. Ribavirin (RBV) has been used to treat RSV-infected LTRs with limited data. Methods. A retrospective study… read more here.
Keywords: infection lung; rbv; oral rbv; syncytial virus ... See more keywords